UPLOAD Filing
Kymera Therapeutics, Inc.
Date: May 7, 2025 · CIK: 0001815442 · Accession: 0000000000-25-004854
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39460
Letter
Re: Kymera Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 001-39460 Dear Bruce Jacobs:
May 7, 2025
Bruce Jacobs Chief Financial Officer Kymera Therapeutics, Inc. 500 North Beacon Street, 4th Floor Watertown, MA 02472
We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 7, 2025 Bruce Jacobs Chief Financial Officer Kymera Therapeutics, Inc. 500 North Beacon Street, 4th Floor Watertown, MA 02472 Re: Kymera Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 001-39460 Dear Bruce Jacobs: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences </TEXT> </DOCUMENT>